Who Owns JSPR?

Jasper Therapeutics, Inc. — Institutional Ownership & 13F Holdings

$0.93

+0.04 (+4.77%)

Market Cap

$21.3M

Shares Outstanding

16,252,570

Institutional Holders

67

Total Inst. Value

$54.6M

% of Float Held

QoQ Holder Change

+16

Institutional data as of Q1 2025

New Positions

13

Closed Positions

30

Increased

20

Decreased

22

Institutional Ownership Trend

Top 10 Institutional Holders(Q1 2025)

#FundValueShares
1Soleus Capital Management, L.P.$6.4M1,494,420
2Velan Capital Investment Management LP$6.2M1,433,828
3Carlyle Group Inc.$4.6M1,066,189
4Qiming U.S. Ventures Management, LLCNew$4.0M928,964
5BlackRock, Inc.$3.4M787,605
6T. Rowe Price Investment Management, Inc.$3.0M702,757
7VANGUARD GROUP INC$2.9M679,452
8MORGAN STANLEY$2.8M653,984
9Integral Health Asset Management, LLC$2.5M575,000
10Rock Springs Capital Management LP$2.3M545,171

Biggest Buyers & Sellers This Quarter

Related Stocks

Frequently Asked Questions

How many institutional investors hold JSPR?

As of Q1 2025, 67 institutional investors report holding JSPR (Jasper Therapeutics, Inc.) in their 13F filings.

Which hedge fund owns the most JSPR?

The largest institutional holder of JSPR is Soleus Capital Management, L.P. with $6.4M in shares.

Are institutions buying or selling JSPR?

This quarter, 13 institutions opened new positions in JSPR and 30 closed their positions.

What is 13F institutional ownership?

SEC Form 13F is a quarterly report filed by institutional investment managers with over $100M in qualifying assets. It discloses their US equity holdings, providing transparency into what the largest investors are buying and selling.

How often is institutional ownership data updated?

13F filings are due 45 days after each calendar quarter end (May 15, Aug 14, Nov 14, Feb 14). Data is updated on HedgeTrace as new filings are processed.